• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在伊朗 COVID-19 病例为期一年的随访中,SARS-CoV-2 再感染率。

SARS-CoV-2 re-infection rate in Iranian COVID-19 cases within one-year follow-up.

机构信息

COVID-19 National Reference Laboratory, Pasteur Institute of Iran, Tehran, Iran; Department of Arboviruses and Viral Hemorrhagic Fevers (National Reference Laboratory), Pasteur Institute of Iran, Tehran, Iran.

Department of Influenza and Other Respiratory Viruses of Pasteur Institute of Iran, Tehran, Iran.

出版信息

Microb Pathog. 2021 Dec;161(Pt B):105296. doi: 10.1016/j.micpath.2021.105296. Epub 2021 Nov 18.

DOI:10.1016/j.micpath.2021.105296
PMID:34801646
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8599135/
Abstract

Since the COVID-19 pandemic initiation, the possibility of re-infection has been unclearly present. Although herd immunity has a potential reliance through natural infection, human corona viruses has the ability to subvert immunity and re-infection happens for seasonal corona viruses. Currently, the frequency of SARS-CoV-2 re-infection incidence is not exactly defined. In this study we aimed at determination of SARS-CoV-2 re-infection rate in Iranian population. In a total of 5696 COVID-19 suspicious individuals, RT-PCR was applied to diagnose the infection. The confirmed patients were followed for 12 months and serology tests were applied to measure the specific antibodies. Among 1492 confirmed COVID-19 cases, five individuals experienced the subsequent infection. The re-infection/reactivation incidence rate was totally 0.33% after one year of follow-up. The interval ranged from 63 to 156 days. All the cases had viral mutations in the second episode of the infection. All of them were symptomatic cases with moderate severity. The estimated rate of SARS-CoV-2 in Persian population is therefore rare and natural infection seems to induce good protection against re-infection which clarifies that mass vaccination can hugely affect the society.

摘要

自 COVID-19 大流行开始以来,再次感染的可能性一直不太明确。虽然通过自然感染获得群体免疫具有一定的可能性,但人类冠状病毒有能力颠覆免疫力,而且季节性冠状病毒也会再次感染。目前,SARS-CoV-2 再次感染的频率尚不清楚。在这项研究中,我们旨在确定伊朗人群中 SARS-CoV-2 的再次感染率。在总共 5696 名 COVID-19 疑似个体中,应用 RT-PCR 诊断感染。确诊患者被随访 12 个月,并应用血清学检测来测量特定抗体。在 1492 例确诊的 COVID-19 病例中,有 5 人随后发生了感染。在 1 年的随访后,再次感染/再激活的发生率为 0.33%。间隔时间为 63 至 156 天。所有病例在第二次感染时均发生了病毒突变。所有病例均为有症状的中度严重程度病例。因此,估计 SARS-CoV-2 在波斯人群中的发生率很低,自然感染似乎能很好地预防再次感染,这表明大规模疫苗接种可以对社会产生巨大影响。

相似文献

1
SARS-CoV-2 re-infection rate in Iranian COVID-19 cases within one-year follow-up.在伊朗 COVID-19 病例为期一年的随访中,SARS-CoV-2 再感染率。
Microb Pathog. 2021 Dec;161(Pt B):105296. doi: 10.1016/j.micpath.2021.105296. Epub 2021 Nov 18.
2
Clinical characteristics of SARS-CoV-2 by re-infection vs. reactivation: a case series from Iran.再感染与再激活的 SARS-CoV-2 的临床特征:来自伊朗的病例系列。
Eur J Clin Microbiol Infect Dis. 2021 Aug;40(8):1713-1719. doi: 10.1007/s10096-021-04221-6. Epub 2021 Mar 18.
3
High Post-Infection Protection after COVID-19 among Healthcare Workers: A Population-Level Observational Study.新冠病毒感染后对医护人员的高保护作用:一项基于人群的观察性研究。
Iran J Med Sci. 2024 Apr 1;49(4):247-258. doi: 10.30476/IJMS.2023.97708.2951. eCollection 2024 Apr.
4
A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.一项评估 SARS-CoV-2 疫苗(灭活,Vero 细胞)有效性和安全性的随机、双盲、安慰剂对照 III 期临床试验:一项随机对照试验研究方案的结构化总结。
Trials. 2021 Apr 13;22(1):276. doi: 10.1186/s13063-021-05180-1.
5
Clinical Presentation of Cases with SARS-CoV-2 Reinfection/ Reactivation.SARS-CoV-2 再感染/再激活病例的临床表现。
J Assoc Physicians India. 2021 Jan;69(1):16-18.
6
Re-positive PCR of SARS-CoV-2 in health care persons during COVID-19 pandemic.在 COVID-19 大流行期间,医护人员中 SARS-CoV-2 的 PCR 复阳。
Cell Mol Biol (Noisy-le-grand). 2022 Feb 4;67(5):138-143. doi: 10.14715/cmb/2021.67.5.19.
7
Reinfection of SARS-CoV-2 - analysis of 23 cases from the literature.SARS-CoV-2 再感染 - 文献中 23 例分析。
Infect Dis (Lond). 2021 Jul;53(7):479-485. doi: 10.1080/23744235.2021.1905174. Epub 2021 Apr 13.
8
Protection against symptomatic infection with delta (B.1.617.2) and omicron (B.1.1.529) BA.1 and BA.2 SARS-CoV-2 variants after previous infection and vaccination in adolescents in England, August, 2021-March, 2022: a national, observational, test-negative, case-control study.2021 年 8 月至 2022 年 3 月,英国青少年在先前感染和接种疫苗后对 delta(B.1.617.2)和 omicron(B.1.1.529)BA.1 和 BA.2 SARS-CoV-2 变异株的症状性感染的保护作用:一项全国性、观察性、基于检测的病例对照研究。
Lancet Infect Dis. 2023 Apr;23(4):435-444. doi: 10.1016/S1473-3099(22)00729-0. Epub 2022 Nov 24.
9
Asymptomatic COVID-19 re-infection in a Japanese male by elevated half-maximal inhibitory concentration (IC) of neutralizing antibodies.日本男性因中和抗体半数最大抑制浓度(IC)升高而出现无症状 COVID-19 再感染。
J Infect Chemother. 2021 Jul;27(7):1063-1067. doi: 10.1016/j.jiac.2021.04.017. Epub 2021 Apr 24.
10
Reinfection or Reactivation of Severe Acute Respiratory Syndrome Coronavirus 2: A Systematic Review.再次感染或严重急性呼吸综合征冠状病毒 2 型的激活:系统评价。
Front Public Health. 2021 Jun 11;9:663045. doi: 10.3389/fpubh.2021.663045. eCollection 2021.

引用本文的文献

1
Improving Vaccine Response through Probiotics and Micronutrient Supplementation: Evaluating the Role of TLR5 in Adult Female BALB/c Mice.通过益生菌和微量营养素补充改善疫苗反应:评估Toll样受体5在成年雌性BALB/c小鼠中的作用
Curr Pharm Des. 2025;31(3):233-242. doi: 10.2174/0113816128310203240823053538.
2
Safety and efficiency of COVID-19 vaccine in North Africa.北非地区 COVID-19 疫苗的安全性和有效性。
Hum Vaccin Immunother. 2024 Dec 31;20(1):2306703. doi: 10.1080/21645515.2024.2306703. Epub 2024 Feb 2.
3
Lessons from COVID-19 Pandemic: A Successful Policy and Practice by Pasteur Institute of Iran.从 COVID-19 大流行中吸取的教训:伊朗巴斯德研究所的成功政策和实践。
Iran Biomed J. 2024 Jan 1;28(1):1-7. doi: 10.61186/ibj.3964. Epub 2023 Oct 11.
4
Psychometric properties of the COVID-19 Yorkshire Rehabilitation Scale: Post-Covid-19 syndrome in Iranian elderly population.《COVID-19 约克郡康复量表的心理测量学特性:伊朗老年人群中的新冠后综合征》
BMC Infect Dis. 2024 Jan 11;24(1):77. doi: 10.1186/s12879-024-08991-0.
5
Epidemiological surveillance of respiratory viral infections in SARS-CoV-2-negative samples during COVID-19 pandemic in Iran.伊朗 COVID-19 大流行期间 SARS-CoV-2 阴性样本中呼吸道病毒感染的流行病学监测。
Virol J. 2023 Dec 13;20(1):296. doi: 10.1186/s12985-023-02226-5.
6
Incidence and outcome of SARS-CoV-2 reinfection in the pre-Omicron era: A global systematic review and meta-analysis.在奥密克戎出现之前,SARS-CoV-2 再感染的发生率和结局:一项全球系统评价和荟萃分析。
J Glob Health. 2023 Nov 24;13:06051. doi: 10.7189/jogh.13.06051.
7
Immunogenicity and safety of heterologous boost immunization with PastoCovac Plus against COVID-19 in ChAdOx1-S or BBIBP-CorV primed individuals.异源加强免疫 PastoCovac Plus 对 ChAdOx1-S 或 BBIBP-CorV 初免个体的 COVID-19 免疫原性和安全性。
PLoS Pathog. 2023 Nov 1;19(11):e1011744. doi: 10.1371/journal.ppat.1011744. eCollection 2023 Nov.
8
Evaluation of PastoCovac plus vaccine as a booster dose on vaccinated individuals with inactivated COVID-19 vaccine.评估PastoCovac加强疫苗对已接种新冠病毒灭活疫苗个体的效果。
Heliyon. 2023 Sep 29;9(10):e20555. doi: 10.1016/j.heliyon.2023.e20555. eCollection 2023 Oct.
9
The prevalence of and factors related to reinfection with COVID-19 in Ahvaz, Iran: A comparative cross-sectional study.伊朗阿瓦士地区新冠病毒再次感染的患病率及相关因素:一项比较性横断面研究。
Health Sci Rep. 2023 Jul 21;6(7):e1420. doi: 10.1002/hsr2.1420. eCollection 2023 Jul.
10
PastoCovac and PastoCovac Plus as protein subunit COVID-19 vaccines led to great humoral immune responses in BBIP-CorV immunized individuals.巴斯德科瓦克和巴斯德科瓦克加作为蛋白质亚单位 COVID-19 疫苗,在 BBIP-CorV 免疫个体中引起了强烈的体液免疫反应。
Sci Rep. 2023 May 18;13(1):8065. doi: 10.1038/s41598-023-35147-y.

本文引用的文献

1
SARS-CoV-2 antibody-positivity protects against reinfection for at least seven months with 95% efficacy.新冠病毒抗体阳性可提供至少七个月的再感染防护,有效率达95%。
EClinicalMedicine. 2021 May;35:100861. doi: 10.1016/j.eclinm.2021.100861. Epub 2021 Apr 28.
2
SARS-CoV-2 seropositivity and subsequent infection risk in healthy young adults: a prospective cohort study.SARS-CoV-2 血清阳性率及健康青年随后的感染风险:一项前瞻性队列研究。
Lancet Respir Med. 2021 Jul;9(7):712-720. doi: 10.1016/S2213-2600(21)00158-2. Epub 2021 Apr 15.
3
SARS-CoV-2 infection rates of antibody-positive compared with antibody-negative health-care workers in England: a large, multicentre, prospective cohort study (SIREN).英格兰抗体阳性与抗体阴性医护人员的 SARS-CoV-2 感染率:一项大型、多中心、前瞻性队列研究(SIREN)。
Lancet. 2021 Apr 17;397(10283):1459-1469. doi: 10.1016/S0140-6736(21)00675-9. Epub 2021 Apr 9.
4
SARS-CoV-2 presented moderately during two episodes of the infection with lack of antibody responses.SARS-CoV-2 在两次感染过程中表现为中度,抗体反应缺乏。
Virus Res. 2021 Jul 2;299:198421. doi: 10.1016/j.virusres.2021.198421. Epub 2021 Apr 6.
5
SARS-CoV-2 re-infection: development of an epidemiological definition from India.SARS-CoV-2 再感染:来自印度的流行病学定义的制定。
Epidemiol Infect. 2021 Mar 26;149:e82. doi: 10.1017/S0950268821000662.
6
Assessment of protection against reinfection with SARS-CoV-2 among 4 million PCR-tested individuals in Denmark in 2020: a population-level observational study.2020 年丹麦对 400 万 PCR 检测个体进行的 SARS-CoV-2 再感染保护评估:一项基于人群的观察性研究。
Lancet. 2021 Mar 27;397(10280):1204-1212. doi: 10.1016/S0140-6736(21)00575-4. Epub 2021 Mar 17.
7
Prolonged viral shedding and antibody persistence in patients with COVID-19.COVID-19 患者的病毒持续排出和抗体持续存在。
Microbes Infect. 2021 May-Jun;23(4-5):104810. doi: 10.1016/j.micinf.2021.104810. Epub 2021 Mar 17.
8
Clinical characteristics of SARS-CoV-2 by re-infection vs. reactivation: a case series from Iran.再感染与再激活的 SARS-CoV-2 的临床特征:来自伊朗的病例系列。
Eur J Clin Microbiol Infect Dis. 2021 Aug;40(8):1713-1719. doi: 10.1007/s10096-021-04221-6. Epub 2021 Mar 18.
9
SARS-CoV-2 re-infection risk in Austria.奥地利的 SARS-CoV-2 再感染风险。
Eur J Clin Invest. 2021 Apr;51(4):e13520. doi: 10.1111/eci.13520. Epub 2021 Feb 21.
10
SARS-CoV‑2, a virus with many faces: a series of cases with prolonged persistence of COVID-19 symptoms.SARS-CoV-2,一个多面的病毒:一系列 COVID-19 症状持续时间延长的病例。
Wien Med Wochenschr. 2021 Feb;171(1-2):3-6. doi: 10.1007/s10354-020-00793-8. Epub 2020 Dec 14.